395 related articles for article (PubMed ID: 31369184)
21. Establishment of Asia-Pacific Network for Enterovirus Surveillance.
Chiu ML; Luo ST; Chen YY; Chung WY; Duong V; Dussart P; Chan YF; Perera D; Ooi MH; Thao NTT; Truong HK; Lee MS
Vaccine; 2020 Jan; 38(1):1-9. PubMed ID: 31679864
[TBL] [Abstract][Full Text] [Related]
22. Novel recombinant chimeric virus-like particle is immunogenic and protective against both enterovirus 71 and coxsackievirus A16 in mice.
Zhao H; Li HY; Han JF; Deng YQ; Zhu SY; Li XF; Yang HQ; Li YX; Zhang Y; Qin ED; Chen R; Qin CF
Sci Rep; 2015 Jan; 5():7878. PubMed ID: 25597595
[TBL] [Abstract][Full Text] [Related]
23. T Cell Immunity To Enterovirus 71 Infection In Humans And Implications For Vaccine Development.
Yee PTI; Poh CL
Int J Med Sci; 2018; 15(11):1143-1152. PubMed ID: 30123051
[TBL] [Abstract][Full Text] [Related]
24. Vaccine candidates generated by codon and codon pair deoptimization of enterovirus A71 protect against lethal challenge in mice.
Lee MHP; Tan CW; Tee HK; Ong KC; Sam IC; Chan YF
Vaccine; 2021 Mar; 39(12):1708-1720. PubMed ID: 33640144
[TBL] [Abstract][Full Text] [Related]
25. Virulence of Enterovirus A71 Fluctuates Depending on the Phylogenetic Clade Formed in the Epidemic Year and Epidemic Region.
Kobayashi K; Nishimura H; Mizuta K; Nishizawa T; Chu ST; Ichimura H; Koike S
J Virol; 2021 Nov; 95(23):e0151521. PubMed ID: 34523967
[TBL] [Abstract][Full Text] [Related]
26. Immunogenicity, safety, cross-reaction, and immune persistence of an inactivated enterovirus A71 vaccine in children aged from two months to 11 years in Taiwan.
Huang LM; Chiu CH; Chiu NC; Lin CY; Li MT; Kuo TY; Weng YJ; Hsieh EF; Tai IC
Vaccine; 2019 Mar; 37(13):1827-1835. PubMed ID: 30803843
[TBL] [Abstract][Full Text] [Related]
27. The stability and immunogenicity of formalin-inactivated Enterovirus A71 whole virion vaccine after ten years of low temperature storage.
Shen YS; Chow YH; Fang CY; Wu SR; Chen CH; Huang MH; Liao CL; Chiang JR; Liu CC
J Microbiol Immunol Infect; 2023 Dec; 56(6):1121-1128. PubMed ID: 37919172
[TBL] [Abstract][Full Text] [Related]
28. Antivirals and vaccines for Enterovirus A71.
Lin JY; Kung YA; Shih SR
J Biomed Sci; 2019 Sep; 26(1):65. PubMed ID: 31481071
[TBL] [Abstract][Full Text] [Related]
29. Advances in Antigenic Peptide-Based Vaccine and Neutralizing Antibodies against Viruses Causing Hand, Foot, and Mouth Disease.
Anasir MI; Poh CL
Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30871133
[TBL] [Abstract][Full Text] [Related]
30. Development of a multivalent enterovirus subunit vaccine based on immunoinformatic design principles for the prevention of HFMD.
Deng H; Yu S; Guo Y; Gu L; Wang G; Ren Z; Li Y; Li K; Li R
Vaccine; 2020 Apr; 38(20):3671-3681. PubMed ID: 32247566
[TBL] [Abstract][Full Text] [Related]
31. [Analysis on epidemiological characteristics of enterovirus 71 cases of hand-foot-mouth disease based on the active monitoring in Guangdong Province in 2011-2015].
Xie DS; He JF; Yang F; Li H; Kang M; Zhang M; Ye X; Tan XH; Ni XH; Hu L; Sun LM
Zhonghua Yu Fang Yi Xue Za Zhi; 2018 Jul; 52(7):738-742. PubMed ID: 29996302
[No Abstract] [Full Text] [Related]
32. Neutralizing antibody against Enterovirus-A71 in Thai children: A longitudinal study from birth to age 4 years.
Puenpa J; Chansaenroj J; Auphimai C; Srimuan D; Thatsanathorn T; Poovorawan Y; Wanlapakorn N
Vaccine; 2020 Nov; 38(48):7638-7644. PubMed ID: 33067033
[TBL] [Abstract][Full Text] [Related]
33. Clinical characteristics and managements of severe hand, foot and mouth disease caused by enterovirus A71 and coxsackievirus A16 in Shanghai, China.
Cai K; Wang Y; Guo Z; Yu H; Li H; Zhang L; Xu S; Zhang Q
BMC Infect Dis; 2019 Mar; 19(1):285. PubMed ID: 30917800
[TBL] [Abstract][Full Text] [Related]
34. An enterovirus A71 virus-like particle with replaced loops confers partial cross-protection in mice.
Liu X; Zhu H; Wang M; Zhang N; Wang J; Tan W; Wu G; Yu P; Liu H; Liu Q
Virus Res; 2023 Nov; 337():199235. PubMed ID: 37788720
[TBL] [Abstract][Full Text] [Related]
35. Immunogenicity and performance of an enterovirus 71 virus-like-particle vaccine in nonhuman primates.
Lim PY; Hickey AC; Jamiluddin MF; Hamid S; Kramer J; Santos R; Bossart KN; Cardosa MJ
Vaccine; 2015 Nov; 33(44):6017-24. PubMed ID: 26271825
[TBL] [Abstract][Full Text] [Related]
36. Development of Novel Vaccines against Enterovirus-71.
Yee PT; Poh CL
Viruses; 2015 Dec; 8(1):. PubMed ID: 26729152
[TBL] [Abstract][Full Text] [Related]
37. A Selective Bottleneck Shapes the Evolutionary Mutant Spectra of Enterovirus A71 during Viral Dissemination in Humans.
Huang SW; Huang YH; Tsai HP; Kuo PH; Wang SM; Liu CC; Wang JR
J Virol; 2017 Dec; 91(23):. PubMed ID: 28931688
[TBL] [Abstract][Full Text] [Related]
38. Novel strategies for the development of hand, foot, and mouth disease vaccines and antiviral therapies.
Fang CY; Liu CC
Expert Opin Drug Discov; 2022 Jan; 17(1):27-39. PubMed ID: 34382876
[TBL] [Abstract][Full Text] [Related]
39. Hand-Foot-and-Mouth Disease-Associated Enterovirus and the Development of Multivalent HFMD Vaccines.
Zhang X; Zhang Y; Li H; Liu L
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613612
[TBL] [Abstract][Full Text] [Related]
40. Enterovirus A71 vaccine effectiveness in preventing enterovirus A71 infection among medically-attended hand, foot, and mouth disease cases, Beijing, China.
Wang X; An Z; Huo D; Jia L; Li J; Yang Y; Liang Z; Wang Q; Wang H
Hum Vaccin Immunother; 2019; 15(5):1183-1190. PubMed ID: 30779680
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
